Liver Disease Treatment Market Growth & Forecast | 2022-2028

Market Insights

The Liver Disease Treatment Market was estimated at US$ 21.71 billion in 2021 and is expected to grow at a CAGR of 6.16% during 2022-2028 to reach US$ 31.2 billion in 2028.

Wish to get a free sample? Register Here

What is Liver Disease Treatment?

The basic activities of the liver, which is a crucial organ for the body and performs more than 500 different tasks, include the generation and excretion of bile as well as the elimination of bilirubin, cholesterol, hormones, and medications. It purifies and detoxifies the blood while battling infection and poisons. A variety of intricate disorders that affect the liver collectively make up liver disease. A range of acute and chronic illnesses, such as hepatitis A, B, and C, non-alcoholic fatty liver disease, liver cancer, bile duct cancer, liver cell adenoma, and liver cirrhosis, can be brought on by liver malfunction, which can be fatal. Hemochromatosis, hyperoxaluria, and Wilson's disease are examples of liver conditions that are inherited.

The medical attention provided to a patient with a liver illness is referred to as liver disease treatment. Additionally, the course of treatment involves taking a variety of medications to treat various liver disorders. For instance, the hepatitis B virus, which causes hepatitis B, is a liver illness (HBV). Antiviral medications are used to treat this disorder, and vaccinations can also be used to prevent it. Immunoglobulin is another medication used in the treatment of hepatitis. Similarly, chemotherapeutic medicines and targeted therapy are used to treat liver cancer. Additionally, corticosteroids are used to treat several autoimmune liver problems. Furthermore, immunosuppressant medications are frequently used to avoid organ rejection in liver-related disorders, which frequently necessitate liver transplantation.

The most typical signs of liver illness are swelling in the legs and belly, easy bruising, changes in the color of the urine and feces, and jaundice, or yellowing of the skin and eyes. Detecting liver damage and assisting in the diagnosis of liver illnesses are both possible using imaging and liver function testing. Immunosuppressants, chemotherapeutic agents, targeted therapy, vaccinations, antiviral medications, immunoglobulins, and corticosteroids make up the majority of the treatments for liver disease. A variety of liver ailments, such as hepatitis, autoimmune disorders, non-alcoholic fatty liver, and hereditary abnormalities are also treated using these products.

Market Dynamics

The main drivers driving the market's expansion are the rise in the geriatric population, bad diets, unhealthy lifestyles caused by increased stress, and increased alcohol usage. One of the main causes of liver problems is an increase in alcohol use. Alcohol changes the molecules that remove and break down scar tissue. This implies that normal, healthy cells are replaced by scar tissue in the liver, where scar tissue builds up. As a result, the liver is unable to perform as it should, and it could fail and cause death. Acute alcoholic hepatitis, alcoholic cirrhosis, and alcoholic fatty liver disease are all examples of alcohol-related liver disease (ARLD). About 95.2 thousand people died from alcohol-related causes in 2021, with liver disorders accounting for 31.08% of those fatalities, according to the National Center for Drug Abuse Statistics. The primary killer, responsible for 19.1% of all alcohol-related deaths, is alcoholic liver disease. By providing the proper liver treatment at the appropriate time, such significant mortality can be avoided, which spurs the market's expansion.

An enormous increase in government and non-government awareness initiatives to treat liver illnesses is the primary driver driving the growth of the global market for the treatment of liver disease. Additionally, it is predicted that during the projected period, the prevalence of liver problems will rise, particularly in countries in Latin America and the Middle East. However, it is projected that the market won't expand due to the high development costs of medications used to treat liver illness.

The analysis period's expansion of the worldwide liver disease treatment market may be constrained by the requirement for substantial expenditure in drug development. In addition, strict government regulations by the U.S. Food and Drug Administration (FDA) and the Medicines and Healthcare Products Regulatory Agency (MHRA) as well as the side effects connected with medications are some of the factors impeding the growth of the global market.

Several investments/guidelines in the industry have been directed in recent years, which would boost the overall market. Some of them are:

The operational instructions for the integration of NAFLD (non-alcoholic fatty liver disease) with the NPCDCS were introduced in February 2021 by Dr. Harsh Vardhan, the Union Minister of Health & Family Welfare (National Programme for Prevention & Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke).

Segments Analysis

By Treatment Type

The market is further segmented into antiviral drugs, immunosuppressants, vaccines, immunoglobulins, corticosteroids, targeted therapy, and chemotherapy. It is anticipated that over the projected period, the antiviral medications subsegment of the therapy type segment would dominate the market. Due to the many advantages antiviral medications have, there has been an increase in their research and development.

By Disease Type

The market is segmented into hepatitis, autoimmune diseases, non-alcoholic fatty liver disease (NAFLD), cancer, genetic disorders, and others. The disease type segment's non-alcoholic fatty liver disease sub-segment is anticipated to grow extensively during the forecast period, propelling it to the top of the global market. This is mostly attributable to the rise in diabetes cases around the world, greater liver disease awareness in developing nations, and an increase in the number of obese people in the world.

Regional Analysis

The liver disease treatment market is broken down geographically into areas like North America, Europe, Asia-Pacific, and the Rest of the World (RoW). The region with the highest growth is expected to be Asia-Pacific. The increased demand for therapies for progressive and severe liver disease, particularly in countries like India, China, and South Korea in this area, is largely to blame for the market's expansion.

Key Players

The following are the major players in the liver disease treatment market:

• ‎AbbVie
• Bayer AG
• Bristol Myers Squibb (BMS)
• F. Hoffmann-La Roche Ltd
• Gilead Sciences, Inc.
• GlaxoSmithKline
• Johnson & Johnson Services, Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi 

Report Features

This report provides market intelligence most comprehensively. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.

What Deliverables Will You Get in this Report?

Research Methodology

This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools. More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles, have been leveraged to gather the data. We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and industry experts to obtain both qualitative and quantitative insights.

Customization Options

With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

Company Profiling

• Detailed profiling of additional market players (up to three players)
• SWOT analysis of key players (up to three players)

Competitive Benchmarking

• Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances

Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com

Recent Developments

It is projected that the existence of numerous big and minor players, as well as a growing number of international players, will foster the market's expansion. These businesses employ a variety of techniques to improve their market position, including the creation of new products and services using cutting-edge technology, collaborations with other businesses, the extension of their retail footprint, and business investments. For instance:

• American biopharmaceutical company Gilead Sciences said in June 2021 that it would seek US approval for "Hepcludex", an antiviral medication for hepatitis D virus (HDV). Excellent entry inhibitor Hepcludex is authorized by the European Commission and registered in Russia as "Myrcludex B."
• For the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH), Zydus Cadila's new medication application for saroglitazar was approved by the Drug Controller General of India (DCGI) in March 2020.